215 related articles for article (PubMed ID: 24559157)
1. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.
Goldberg A; Geppert T; Schiopu E; Frech T; Hsu V; Simms RW; Peng SL; Yao Y; Elgeioushi N; Chang L; Wang B; Yoo S
Arthritis Res Ther; 2014 Feb; 16(1):R57. PubMed ID: 24559157
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
[TBL] [Abstract][Full Text] [Related]
3. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
White B; Leon F; White W; Robbie G
Clin Ther; 2009 Apr; 31(4):728-40. PubMed ID: 19446146
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody.
Wang B; Higgs BW; Chang L; Vainshtein I; Liu Z; Streicher K; Liang M; White WI; Yoo S; Richman L; Jallal B; Roskos L; Yao Y
Clin Pharmacol Ther; 2013 Jun; 93(6):483-92. PubMed ID: 23511714
[TBL] [Abstract][Full Text] [Related]
5. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.
Parker JM; Oh CK; LaForce C; Miller SD; Pearlman DS; Le C; Robbie GJ; White WI; White B; Molfino NA;
BMC Pulm Med; 2011 Feb; 11():14. PubMed ID: 21356110
[TBL] [Abstract][Full Text] [Related]
6. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
Petri M; Wallace DJ; Spindler A; Chindalore V; Kalunian K; Mysler E; Neuwelt CM; Robbie G; White WI; Higgs BW; Yao Y; Wang L; Ethgen D; Greth W
Arthritis Rheum; 2013 Apr; 65(4):1011-21. PubMed ID: 23400715
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
Meininger V; Pradat PF; Corse A; Al-Sarraj S; Rix Brooks B; Caress JB; Cudkowicz M; Kolb SJ; Lange D; Leigh PN; Meyer T; Milleri S; Morrison KE; Orrell RW; Peters G; Rothstein JD; Shefner J; Lavrov A; Williams N; Overend P; Price J; Bates S; Bullman J; Krull D; Berges A; Abila B; Meno-Tetang G; Wurthner J
PLoS One; 2014; 9(5):e97803. PubMed ID: 24841795
[TBL] [Abstract][Full Text] [Related]
8. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.
Haluska P; Menefee M; Plimack ER; Rosenberg J; Northfelt D; LaVallee T; Shi L; Yu XQ; Burke P; Huang J; Viner J; McDevitt J; LoRusso P
Clin Cancer Res; 2014 Sep; 20(18):4747-57. PubMed ID: 25024259
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.
Bissonnette R; Papp K; Maari C; Yao Y; Robbie G; White WI; Le C; White B
J Am Acad Dermatol; 2010 Mar; 62(3):427-36. PubMed ID: 20159310
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
Tanaka Y; Takeuchi T; Okada M; Ishii T; Nakajima H; Kawai S; Nagashima T; Hayashi N; Wang L; Tummala R
Mod Rheumatol; 2020 Jan; 30(1):101-108. PubMed ID: 30793642
[No Abstract] [Full Text] [Related]
15. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
Li X; Li B; Wang M; Fang M; Lou J; Liu J; Chen H; Ding Y
BioDrugs; 2024 Mar; 38(2):313-321. PubMed ID: 38148466
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Gaudinski MR; Coates EE; Novik L; Widge A; Houser KV; Burch E; Holman LA; Gordon IJ; Chen GL; Carter C; Nason M; Sitar S; Yamshchikov G; Berkowitz N; Andrews C; Vazquez S; Laurencot C; Misasi J; Arnold F; Carlton K; Lawlor H; Gall J; Bailer RT; McDermott A; Capparelli E; Koup RA; Mascola JR; Graham BS; Sullivan NJ; Ledgerwood JE;
Lancet; 2019 Mar; 393(10174):889-898. PubMed ID: 30686586
[TBL] [Abstract][Full Text] [Related]
17. A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors.
Murakami H; Ikeda M; Okusaka T; Inaba Y; Iguchi H; Yagawa K; Yamamoto N
Cancer Chemother Pharmacol; 2015 Sep; 76(3):631-9. PubMed ID: 26223436
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.
Gow JM; Tsuji WH; Williams GJ; Mytych D; Sciberras D; Searle SL; Mant T; Gibbs JP
Arthritis Res Ther; 2015 Oct; 17():282. PubMed ID: 26449617
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
Sáez-Llorens X; Castaño E; Null D; Steichen J; Sánchez PJ; Ramilo O; Top FH; Connor E
Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
